Logan Reid
The regulation of scientific research in hospitals is a complex process involving multiple organizations and laws. The primary goal of these regulations is to protect the rights, welfare, and well-being of human subjects involved in research, as well as to ensure ethical conduct and compliance with the law. In the United States, the Food and Drug Administration (FDA) and the Department of Justice (DOJ) play a significant role in regulating clinical trials and human subject protection. The FDA's bioresearch monitoring (BIMO) program, for example, conducts on-site inspections and data audits to monitor FDA-regulated research. Additionally, the Office for Human Research Protections (OHRP), a part of the U.S. Department of Health and Human Services (HHS), provides leadership in protecting the rights and welfare of human subjects in research conducted or supported by HHS. The OHRP enforces the Common Rule and other HHS regulations, ensuring compliance and responding to potential violations. Universities, hospitals, and research institutions also have Institutional Review Boards (IRBs) that review and approve research proposals, assessing the risks and benefits associated with human subjects and ensuring adequate protection and consent.
| Characteristics | Values |
|---|---|
| Regulatory Body | Office for Human Research Protections (OHRP) |
| Parent Department | U.S. Department of Health and Human Services (HHS) |
| Function | Provides leadership in the protection of the rights, welfare, and well-being of human subjects |
| Rules | Common Rule (2018 revision) |
| Subparts A, B, C, and D | |
| Compliance | Works with institutions to ensure compliance with regulations |
| Responds to complaints about potential violations | |
| Provides clarification and guidance | |
| Education | Educates researchers and staff on ethical expectations |
| Committees | Institutional Review Boards (IRBs) |
| Secretary's Advisory Committee on Human Research Protections (SACHRP) |
Explore related products
What You'll Learn
The role of the Office for Human Research Protections (OHRP)
The Office for Human Research Protections (OHRP) is a regulatory body within the United States Department of Health and Human Services (DHHS). It was established in 2000 by the United States Secretary of Health and Human Services, Donna Shalala, to oversee research involving human subjects and ensure compliance with DHHS regulations. The OHRP is specifically part of the Office of the Assistant Secretary for Health in the Office of the Secretary of DHHS.
The primary role of the OHRP is to protect the rights, welfare, and well-being of human subjects involved in research conducted or supported by the DHHS. This includes providing leadership, clarification, and guidance on ethical and regulatory issues in biomedical and behavioural research. The OHRP develops educational programs and materials, maintains regulatory oversight, and responds to reports of incidents in DHHS-supported research. They also work with institutions to ensure compliance with regulations and address complaints about potential violations.
One of the key functions of the OHRP is the implementation of 45 CFR 46, a set of regulations for Institutional Review Boards (IRBs). IRBs are committees that ensure researchers follow DHHS rules and ethical guidelines during their studies. The Common Rule, which is part of the HHS regulations, requires that researchers obtain informed consent from participants. This includes providing them with understandable information to make an informed decision about their participation. The OHRP also promotes ethical conduct and regulatory compliance in HHS-supported research studies conducted outside the United States.
The OHRP works closely with DHHS officials, including the Secretary of Health and Human Services and the Assistant Secretary for Health, to ensure that human research policies, plans, and procedures meet ethical standards. The OHRP also supports the Secretary's Advisory Committee on Human Research Protections (SACHRP), which is a committee of researchers and lawyers who provide expert advice to the HHS Secretary on issues related to protecting human subjects in research. The SACHRP holds three annual meetings that are open to the public.
Hospitals in Cayahaga County: A Comprehensive Overview
You may want to see also
Explore related products
![Compliance [Blu-ray]](https://m.media-amazon.com/images/I/712fZO6aOlL._AC_UY218_.jpg)
The Food and Drug Administration (FDA)
The FDA regulates a diverse range of products, including food safety, tobacco, caffeine products, dietary supplements, prescription and over-the-counter medications, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation-emitting devices, cosmetics, animal food and feed, and veterinary products. The FDA ensures the safety, efficacy, and security of these products, and also monitors claims and labelling to ensure accuracy and compliance.
One notable aspect of FDA regulation is the Intentional Adulteration (IA) rule, which mandates that the food industry implements strategies to reduce the risk of compromise in facilities and processes that are vulnerable to contamination. The FDA also regulates drug advertising, requiring companies to advertise drugs only for their approved medical indications and to provide a fair balance between the benefits and risks of the drug in their advertisements.
The FDA frequently collaborates with other federal agencies, such as the Department of Agriculture, the Drug Enforcement Administration, Customs and Border Protection, and the Consumer Product Safety Commission. The FDA is led by the commissioner of food and drugs, who is appointed by the President and reports to the secretary of health and human services. The FDA has a wide reach, with field offices and laboratories across the United States and its territories, as well as employees posted in foreign countries.
Scarface's Health: Hospitalized, but Why?
You may want to see also
Explore related products
Ethical Conduct and Regulatory Compliance
In the United States, the Office for Human Research Protections (OHRP) is the government agency responsible for regulating and enforcing ethical conduct and regulatory compliance in research projects involving human participants. OHRP is part of the U.S. Department of Health and Human Services (HHS) and is responsible for protecting the rights, welfare, and well-being of human subjects involved in research. This includes ensuring compliance with the Common Rule, a set of federal regulations adopted by 15 federal departments and agencies, including HHS, to protect individuals participating in research.
The Common Rule requires that research institutions obtain informed consent from participants and that institutional review boards (IRBs) review and approve research protocols to ensure compliance with ethical guidelines. IRBs are committees that ensure researchers follow HHS rules and ethical standards, and they may be institution-specific or independent. IRBs play a crucial role in safeguarding the rights and welfare of participants by reviewing research protocols, ensuring informed consent, and monitoring the conduct of the research.
In addition to IRBs, other regulatory agencies and departments enforce specific regulations or requirements regarding research with human subjects. For example, the Food and Drug Administration (FDA) requires IRB review and approval for regulated clinical investigations, regardless of whether the participants are institutionalized or not. The FDA also addresses issues such as compensation for IRB members and minimizing liability exposure for IRBs.
Furthermore, the VA's Office of Research & Development has specific federal regulations for conducting research at VA hospitals and institutions, including the protection of human subjects in VA research. The Department of Justice (DOJ) is another regulatory body that has not adopted the Common Rule, and any research subject to DOJ regulations will continue under pre-2018 requirements.
Overall, the regulation of research projects in hospitals involves a complex interplay between government agencies, institutional review boards, and ethical guidelines. The primary goal is to protect the rights and welfare of human participants, ensure informed consent, and maintain compliance with relevant regulations and standards.
Switching HDMI on Hospital TVs: A Quick Guide
You may want to see also
Explore related products
![Law of Governance, Risk Management and Compliance: [Connected Ebook] (Aspen Casebook)](https://m.media-amazon.com/images/I/616gNHR5shL._AC_UY218_.jpg)
Research involving vulnerable populations
Vulnerable populations refer to disadvantaged communities that require the utmost care, specific considerations, and enhanced protections when involved in research. Examples include children, prisoners, pregnant women, the elderly, and those with physical or intellectual disabilities.
The Office for Human Research Protections (OHRP), a part of the US Department of Health and Human Services (HHS), provides leadership in safeguarding the rights, welfare, and well-being of human subjects in research. OHRP ensures compliance with regulations, responds to potential violations, and offers guidance and clarification on ethical and regulatory issues. It also educates researchers on ethical expectations, such as obtaining informed consent from participants and adhering to Common Rule requirements.
The Common Rule, initially published by HHS in 1991 and revised in 2017, is a set of federal rules protecting human research participants. It mandates appropriate review and approval of research by institutional review boards (IRBs) or ERBs, which are committees that ensure researchers follow ethical guidelines. IRBs play a crucial role in safeguarding vulnerable populations by reviewing protocols, assessing risks, and ensuring compliance with ethical standards.
To protect vulnerable populations, IRBs must carefully consider the rationale for their inclusion, potential risks, and the importance of the knowledge gained. They may also involve representatives from specific populations during deliberations. Additionally, researchers must outline procedures for obtaining informed consent, addressing incidental findings, and minimising risks for vulnerable participants.
In the case of children, who are considered a vulnerable population, specific requirements and conditions must be met. These include obtaining assent from the child and permission from their parents or guardians, with additional advocacy required for children who are wards of the state or in specific situations, such as when they are also prisoners.
Oregon State Hospital: Open or Closed?
You may want to see also
The National Research Act of 1974
In the United States, the Office for Human Research Protections (OHRP) provides leadership in the protection of the rights, welfare, and well-being of human subjects involved in research conducted or supported by the U.S. Department of Health and Human Services (HHS). The OHRP is part of the Office of the Assistant Secretary for Health in the Office of the Secretary of HHS.
The National Research Act, enacted in 1974, created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. This group was tasked with developing guidelines for human subject research and overseeing and regulating the use of human experimentation in medicine. The Act was passed following a series of congressional hearings on human-subjects research, directed by Senator Edward Kennedy, and in response to the infamous Tuskegee syphilis study.
The National Commission identified the basic principles of research conduct and made recommendations on how to ensure those principles were followed. As a result of the Commission's work, researchers are now required to obtain voluntary informed consent from all participants in studies done or funded by the Department of Health, Education, and Welfare (DHEW). The Commission also required that all DHEW-supported studies using human subjects be reviewed by Institutional Review Boards (IRBs) to ensure that research protocols meet ethical standards.
The Federal rules that protect people who participate in research were initially published by the Department of Health and Human Services (HHS) and are known as the Common Rule. The Common Rule was simultaneously adopted by 15 Federal departments and agencies in 1991 and was revised in 2017 to reflect changes in research practices. One key protection in the Common Rule is the requirement for appropriate review and approval of research by IRBs, which are committees that ensure researchers follow the HHS rules and ethical guidelines.
Mercy Health's Impressive Hospital Network
You may want to see also
Frequently asked questions
Research projects in hospitals are regulated by Institutional Review Boards (IRBs) set up by the hospitals themselves. IRBs are generally composed of both scientific peers from the hospital and laypersons. They assess the risks and benefits associated with the use of human subjects, as well as the adequacy of the protection and consent of the participants.
The Office for Human Research Protections (OHRP) is part of the U.S. Department of Health and Human Services (HHS). The OHRP provides leadership and protection of the rights, welfare, and well-being of human subjects involved in research conducted or supported by the HHS. It also provides clarification, guidance, and advice on ethical and regulatory issues.
The Common Rule refers to the Federal Policy for the Protection of Human Subjects in research. It outlines the requirements and regulations for conducting research with human subjects. The Common Rule is enforced by the OHRP for research funded by HHS agencies such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).
The Food and Drug Administration (FDA) is a key regulator of clinical trials and human subject protection in the United States. The FDA's bioresearch monitoring (BIMO) program includes on-site inspections and data audits to ensure compliance with federal law and good clinical practice (GCP) regulations. Additionally, the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) are responsible for reviewing new drug applications, conducting clinical trials, and approving drugs based on safety and effectiveness.
